AUPH (Aurinia Pharmaceuticals) Cyclically Adjusted Book per Share: $2.70 (As of Mar. 2026)


AUPH Aurinia Pharmaceuticals Inc AUPH
81 GF Score
Price $15.61
GF Value $14.00
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Cyclically Adjusted Book per Share?

Aurinia Pharmaceuticals AUPH -1.14% 81 Cyclically Adjusted Book per Share is $2.70 as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.00 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aurinia Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $4.341. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Aurinia Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 13.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Aurinia Pharmaceuticals was 13.70% per year. The lowest was -37.60% per year. And the median was -11.70% per year.

As of today (2026-07-04), Aurinia Pharmaceuticals's current stock price is $15.61. Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $2.70. Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 5.78.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aurinia Pharmaceuticals was 21.62. The lowest was 0.40. And the median was 4.11.


Aurinia Pharmaceuticals  (NAS:AUPH) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=15.61/2.70
=5.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aurinia Pharmaceuticals was 21.62. The lowest was 0.40. And the median was 4.11.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 1.88 2.20 2.31 2.57

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 2.42 2.48 2.57 2.70

AUPH vs KOD, ABCL, AGIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


AUPH
81GF Score
Aurinia Pharmaceuticals Inc AUPH
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurinia Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.341/132.2600*132.2600
=4.341

Current CPI (Mar. 2026) = 132.2600.

Aurinia Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.554 102.002 0.718
201609 0.518 101.765 0.673
201612 0.681 101.449 0.888
201703 2.103 102.634 2.710
201706 2.138 103.029 2.745
201709 1.996 103.345 2.554
201712 1.972 103.345 2.524
201803 1.814 105.004 2.285
201806 1.666 105.557 2.087
201809 1.469 105.636 1.839
201812 1.317 105.399 1.653
201903 1.520 106.979 1.879
201906 1.371 107.690 1.684
201909 1.312 107.611 1.613
201912 2.671 107.769 3.278
202003 2.342 107.927 2.870
202006 2.121 108.401 2.588
202009 3.154 108.164 3.857
202012 3.218 108.559 3.921
202103 2.890 110.298 3.465
202106 2.588 111.720 3.064
202109 2.301 112.905 2.695
202112 3.383 113.774 3.933
202203 3.162 117.646 3.555
202206 2.987 120.806 3.270
202209 2.980 120.648 3.267
202212 2.850 120.964 3.116
202303 2.730 122.702 2.943
202306 2.736 124.203 2.913
202309 2.729 125.230 2.882
202312 2.628 125.072 2.779
202403 2.502 126.258 2.621
202406 2.550 127.522 2.645
202409 2.711 127.285 2.817
202412 2.679 127.364 2.782
202503 2.542 129.181 2.603
202506 2.527 129.892 2.573
202509 2.774 130.290 2.816
202512 4.393 130.370 4.457
202603 4.341 132.260 4.341

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $2.70 mean?
Aurinia Pharmaceuticals (AUPH) has a Cyclically Adjusted Book per Share of $2.70 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Aurinia Pharmaceuticals' current Cyclically Adjusted Book per Share is $2.70. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share compare to KOD and ABCL?
Aurinia Pharmaceuticals' Cyclically Adjusted Book per Share of $2.70 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Cyclically Adjusted Book per Share is $2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.00, compared to a current price of $15.61 — trading 11.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $2.70. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Cyclically Adjusted Book per Share is $2.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.61 is trading 11.5% above its estimated GF Value™ of $14.00. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

  • Cyclically Adjusted Book per Share: $2.70
  • GF Value™: $14.00 vs. price of $15.61 (11.5% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges IKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for AUPH

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.61
Price
$14.00
GF Value